AVE 20.0% 0.3¢ avecho biotechnology limited

prophase financials, page-34

  1. 5,760 Posts.
    lightbulb Created with Sketch. 308
    Granted Dougal, I am not a huge fan of going it alone with Elixia for the reasons you have outlined. I think management should be given the opportunity to implement their plans though. It appears that it will be just a component of a roll out that will be licences and partnerships.

    I just want it available to as many people as possible and so long as it works it should get traction. Thus we wait for part 1, the release of the focus group results. Part 2 will hopefully be a very decent partner. Part 3 widespread release. Part 4 money rolling into the bank.

    Regardless of this there are still avenues for poh if it goes pear shaped. Yes it would be several steps back but not the end of the show.

    We will walk on the moon.

 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
0.001(20.0%)
Mkt cap ! $9.507M
Open High Low Value Volume
0.3¢ 0.3¢ 0.3¢ $408 154.2K

Buyers (Bids)

No. Vol. Price($)
61 90794613 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 54998583 13
View Market Depth
Last trade - 16.10pm 19/07/2024 (20 minute delay) ?
AVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.